This page screens the US healthcare sector for companies with net profit margins of at least 18%, refreshed automatically from live data.
DeltaScreener builds this page from the US-listed stocks it tracks, using the following rules. A stock appears here only because it matches these rules; the page title names the criteria and is not a rating of any stock.
Top sectors in the current result set: Healthcare (39).
Click any ticker to open the full stock detail page with financials, valuation ratios, and more.
| # | Ticker | Company | Exchange | Price | Market Cap | P/E | P/B | ROE | ROA | Net Margin | D/E |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | FBIO | Fortress Biotech, Inc. | NASDAQ | $1.87 | $62.4M | 0.64 | 0.4 | 103.52% | 35.31% | 163.32% | 0.39 |
| 2 | RIGL | Rigel Pharmaceuticals, Inc. | NMS | $45.97 | $858.7M | 2.67 | 2.05 | 96.49% | 61.78% | 116.30% | 0.09 |
| 3 | AUPH | Aurinia Pharmaceuticals Inc | NASDAQ | $16.51 | $2.20B | 6.71 | 3.35 | 59.00% | 39.65% | 100.84% | 0.1 |
| 4 | ABUS | Arbutus Biopharma Corporation | NASDAQ | $4.22 | $836.0M | 5.63 | 3.4 | — | 55.85% | 84.23% | 0.01 |
| 5 | ANAB | AnaptysBio, Inc. | NMS | $46.61 | $1.39B | 7.19 | 134.17 | — | 61.75% | 82.37% | 25.47 |
| 6 | INVA | Innoviva, Inc. | NASDAQ | $20.78 | $1.50B | 4.21 | 1.22 | 30.03% | 20.98% | 80.56% | 0.22 |
| 7 | ASND | Ascendis Pharma A/S - Ordinary Share | NASDAQ | $225.25 | $14.05B | 16.85 | 9.14 | — | 33.08% | 71.69% | 0.31 |
| 8 | AGEN | Agenus Inc. | NASDAQ | $6.04 | $272.8M | 2.43 | — | — | 53.28% | 69.34% | -0.2 |
| 9 | LGND | Ligand Pharmaceuticals Incorporated | NASDAQ | $295.54 | $5.89B | 31.21 | 6.48 | 20.06% | 9.02% | 67.88% | 1.17 |
| 10 | QTTB | Q32 Bio Inc. | NASDAQ | $7.52 | $223.9M | 2.95 | 1.1 | 76.88% | 29.16% | 62.87% | 0.05 |
| 11 | LNSR | LENSAR, Inc. | NCM | $5.80 | $71.3M | 5.25 | 5.5 | — | 49.88% | 57.57% | 0.16 |
| 12 | TGTX | TG Therapeutics, Inc. | NASDAQ | $53.97 | $8.26B | 17.83 | 12.74 | 72.30% | 26.93% | 55.22% | 1.25 |
| 13 | KRYS | Krystal Biotech, Inc. | NASDAQ | $316.58 | $9.37B | 38.97 | 7 | 19.34% | 16.09% | 54.82% | 0.01 |
| 14 | CGEN | Compugen Ltd. | NASDAQ | $1.96 | $185.7M | 6.15 | 2.46 | 42.57% | 25.43% | 47.55% | 0.03 |
| 15 | ZVRA | Zevra Therapeutics, Inc. | NASDAQ | $9.94 | $590.3M | 10.4 | 2.72 | 32.77% | 19.25% | 42.82% | 0.01 |
| 16 | UTHR | United Therapeutics Corporation | NASDAQ | $533.12 | $22.87B | 17.74 | 3.57 | 20.18% | 18.16% | 41.56% | 0.01 |
| 17 | CRMD | CorMedix Inc. | NASDAQ | $7.26 | $565.9M | 3.01 | 1.24 | 44.64% | 20.70% | 40.49% | 0.31 |
| 18 | CRON | Cronos Group Inc. - Common Share | NASDAQ | $3.21 | $1.18B | 17.44 | 1.14 | — | 5.91% | 38.95% | 0 |
| 19 | NVO | Novo Nordisk A/S | NYSE | $38.83 | $171.36B | 9.65 | 5.06 | 59.09% | 19.57% | 35.35% | 0.63 |
| 20 | EXEL | Exelixis, Inc. | NASDAQ | $62.23 | $15.64B | 17.78 | 7.96 | 42.49% | 34.50% | 35.33% | 0.09 |
| 21 | VRTX | Vertex Pharmaceuticals Incorporated | NASDAQ | $499.74 | $126.66B | 30.38 | 6.6 | 23.31% | 16.06% | 34.89% | 0.1 |
| 22 | LLY | Eli Lilly and Company | NYSE | $1,257.03 | $1.18T | 39.6 | 31.18 | 92.58% | 18.77% | 33.53% | 1.62 |
| 23 | ACAD | ACADIA Pharmaceuticals Inc. | — | $19.12 | $3.29B | 8.87 | 2.62 | 32.39% | 21.83% | 33.42% | 0.06 |
| 24 | IRWD | Ironwood Pharmaceuticals, Inc. | NASDAQ | $3.50 | $578.3M | 4.52 | — | — | 45.55% | 33.36% | -2.45 |
| 25 | ADMA | ADMA Biologics Inc | NASDAQ | $10.68 | $2.39B | 14.08 | 5.67 | 39.59% | 24.69% | 32.98% | 0.5 |